EU and U.S. Developing New Approaches to Prevent Drug Shortages
This article was originally published in The Gold Sheet
A UK MHRA official said there is a “regulatory dilemma” between meeting GMP enforcement obligations and preventing drug shortages. New changes in the EU GMP Guide aim to take a more proactive approach to drug shortages by requiring early notification by manufacturers, while in the U.S. a new drug shortage prevention program called the Accelerated Recovery Initiative (ARI) is finally getting off the ground.
You may also be interested in...
Five manufacturers have agreed to give IMS Health production and supply information about drugs in short supply; GPhA and IMS are working with FDA to finalize the details of the accelerated recovery initiative.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.